Amylyx Pharmaceuticals, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €228.44M +132.6% €29.87M -134.9% 13.1% +1.0 pp N/A N/A
    (estimated) €98.22M +192.0% -€85.49M -37.3% -87.0% +3.2 pp N/A N/A
    (estimated) €33.64M +48,887.5% -€136.24M +2.9% -405.0% +1.9K pp N/A N/A
    (estimated) €68.68K +∞% -€132.41M +0.0% -192,812.5% -1.9K pp N/A N/A
    (estimated) €0.00 -100.0% -€132.38M -48.9% N/A N/A N/A
    €75.00M -77.1% -€259.03M -712.4% -345.4% -3.6 pp -€143.78M -1,372.7% -191.7% -2.0 pp
    €326.88M +1,612.9% €42.30M -124.8% 12.9% +9.1 pp €11.30M -107.4% 3.5% +8.0 pp
    €19.08M +7,700.0% -€170.29M +125.7% -892.4% +300 pp -€152.24M +138.2% -797.8% +250 pp
    €244.66K -56.2% -€75.44M +96.0% -30,834.7% -240 pp -€63.91M +103.7% -26,121.4% -200 pp
    €557.99K -54.4% -€38.49M +202.6% -6,898.0% -59 pp -€31.37M +242.0% -5,622.5% -49 pp
    €1.22M -€12.72M -1,039.0% -€9.17M -749.4%

    Notifications